Tomasson, M. H., Iida, S., Niesvizky, R., Mohty, M., Bahlis, N. J., Martinez‐Lopez, J., . . . Lesokhin, A. M. (2024). Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study. Wiley. https://doi.org/10.1002/hem3.136
Citazione stile Chigago Style (17a edizione)Tomasson, Michael H., et al. Long‐term Survival and Safety of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma: Update from the MagnetisMM‐3 Study. Wiley, 2024. https://doi.org/10.1002/hem3.136.
Citatione MLA (9a ed.)Tomasson, Michael H., et al. Long‐term Survival and Safety of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma: Update from the MagnetisMM‐3 Study. Wiley, 2024. https://doi.org/10.1002/hem3.136.